stocks logo

TGTX Stock Price Prediction

TG Therapeutics Inc
$
41.060
+0.220(+0.540%)

TGTX Price Prediction Next Week

Analysis and Insights

Fundamental Analysis:

TG Therapeutics (TGTX) has shown strong performance recently, driven by the success of its product Briumvi, which saw a 200% year-over-year increase in sales to $313 million. The company is targeting $540 million in sales for this year, indicating high growth potential. Earnings estimates for the upcoming quarter have been revised 127.5% higher, suggesting strong investor confidence.

Technical Analysis:

The stock is currently trading at $40.94 with a bullish trend. Key technical indicators include:

  • RSI (6-period): 79.33, indicating overbought conditions but still in an uptrend.
  • MACD: Positive at 2.04, showing strong upward momentum.
  • Fibonacci Levels: Resistance at $40.82 and $43.55, with support at $36.40.

Options Activity:

Bullish options activity has been observed, with 2,450 calls traded and increasing implied volatility to 63.04%. This indicates strong investor interest ahead of earnings on May 8th.

Conclusion:

Given the strong fundamentals, positive earnings revisions, and bullish options activity, the stock is expected to continue its upward trend. However, the overbought RSI suggests a potential short-term pullback. The next resistance level at $43.55 is a key target.

Prediction: The stock price is expected to reach $43.20 in the next trading week. Buy recommendation, as the overall trend remains bullish despite minor corrections.

TGTX Similar Chart Price Prediction

The price of TGTX is predicted to go up -21.26%, based on the high correlation periods with DMAC. The similarity of these two price pattern on the periods is 96.82%.

stocks logo

TGTX

Future prediction

Down: -21.26%

Sign Up to See Future Prediction
stocks logo

DMAC

Down: -21.26%Similarity: 96.82%

TGTX Revenue Forecast

TGTX EPS Forecast

TGTX FAQs

What is TGTX revenue forecast for next quarter?

The market consensus for TGTX's revenue in the upcoming quarter is projected to be approximately $117.073M USD.

TGTX VS S&P500

TG Therapeutics Inc
SPDR S&P 500

TGTX Analyst's Forecast

Eric Joseph

JP Morgan

Buy

2024-11-25

Price Target

$30 → $43

Upside

+24.24%

JPMorgan raised the firm's price target on TG Therapeutics to $43 from $30 and keeps an Overweight rating on the shares. The firm says that with a potential SC Briumvi formulation coming into view beginning in the first half of 2025, it updated TG's model to reflect risk adjusted Briumvi forecasts within the at-home/self-administered anti-CD20 segment of relapsing multiple sclerosis. At $3.5B, the analyst's peak Briumvi SC forecast assumes market entry beginning in 2028 and ultimately garnering 35% share of the self-administered CD20 segment. JPMorgan sees an increasingly attractive setup to TG shares in the mid-term.
Tara Bancroft

TD Cowen

Strong Buy

2024-10-29

Price Target

$50

Upside

+94.48%